Abstract
INTRODUCTION
Mixed evidence on how statin use affects risk of Alzheimer’s disease and related dementias (ADRD) may reflect heterogeneity across sociodemographic factors. Few studies have sufficient power to evaluate effect modifiers.
METHODS
Kaiser Permanente Northern California (KPNC) members (n = 705,061; n = 202,937 with sociodemographic surveys) who initiated statins from 2001 to 2010 were matched on age and low-density lipoprotein cholesterol (LDL-C) with non-initiators and followed through 2020 for incident ADRD. Inverse probability-weighted Cox proportional hazards models were used to evaluate effect modification by age, gender, race/ethnicity, education, marital status, income, and immigrant generation.
RESULTS
Statin initiation (vs non-initiation) was not associated with ADRD incidence in any of the 32 subgroups (p > .05). Hazard ratios ranged from 0.964 (95% CI: 0.923 to 1.006) among Asian-identified participants to 1.122 (95% CI: 0.995 to 1.265) in the highest income category.
DISCUSSION
Sociodemographic heterogeneity appears to have little to no influence on the relationship between statin initiation and dementia.
Highlights
The study includes a large and diverse cohort from Kaiser Permanente (N = 705,061).
An emulated trial design of statin initiation on dementia incidence was used.
Effect modification by sociodemographic factors was assessed.
There were no significant Alzheimer’s disease and related dementias (ADRD) risk differences in 32 sociodemographic subgroups (p > 0.05).
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Minhyuk Choi,
Scott C. Zimmerman,
Chen Jiang,
Jingxuan Wang,
Kaitlin Swinnerton,
Thomas J. Hoffmann,
Akinyemi Oni‐Orisan,
Erin L. Ferguson,
Travis Meyers,
Vidhu Choudhary,
Rachel A. Whitmer,
Neil Risch,
Ronald M. Krauss,
Catherine M. Schaefer,
M. Maria Glymour,
Paola Gilsanz | March 29, 2025